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Abstract
Understanding how lentiviruses can infect terminally differentiated, non-dividing cells has proven a
very complex and controversial problem. It is, however, a problem worth investigating, for it is
central to HIV-1 transmission and AIDS pathogenesis. Here I shall attempt to summarise what is
our current understanding for HIV-1 infection of non-dividing cells. In some cases I shall also
attempt to make sense of controversies in the field and advance one or two modest proposals.
Background
DNA viruses and some RNA viruses must access the
nucleus to replicate. This is also the case for lentiviruses
and several excellent reviews have been recently published
on the subject [1-5]. The interior of the nucleus is sepa-
rated from the cytoplasm by a double-layer membrane
contiguous with the ER called the nuclear envelope (NE)
[6]. Embedded in the nuclear envelope are nuclear pores,
which are channel-like macromolecules regulating access
to the nucleus. In simple functional terms, nuclear pores
can be considered like selective filters that allow diffusion
of ions and molecules smaller than 9 nm across the NE
and facilitated passage of larger molecules up to 39 nm in
diameter if certain conditions are met [6]. To date, nuclear
pores are the only known structures regulating ordered
nucleocytoplasmic trafficking. Movement of proteins,
mRNAs, tRNAs, rRNAs and nucleoprotein complexes in
and out from the nucleus obeys to the selective biophysi-
cal nature of nuclear pores [7-11]. Viruses are no excep-
tion to this rule, thus understanding the structural and
functional nature of nuclear pores is crucial to understand
nucleocytoplasmic trafficking of viruses.
Nuclear pores have a maximum diameter of 120 nm, a
depth of 180 nm and an overall mass of approximately
125 MDa in vertebrates [6-12]. Recent 3-D images of
Xenopus Laevis oocytes nuclear pores were obtained using
energy-filtering transmission electron microscopy and
tomographic 3-D reconstruction [13] (Figure 1). The
nuclear pore appears to be constituted of two main ring
moieties, a larger one facing the cytoplasm and a smaller
one facing the nucleus. The two rings are joined together
by a central framework, which is perforated by eight
peripheral holes with a 10 nm diameter. The small holes
are likely to be the site of ion and small molecules traffick-
ing in and out from the nucleus. The central framework
has eight external protuberances that presumably anchor
the pore to the nuclear envelope. Flexible filaments
approximately 50 nm long protrude from the cytoplasmic
ring. Initially these filaments were thought to be impor-
tant for the early steps of nuclear transport, by trapping
and concentrating cargoes at the entry of the pore [14].
However, it has later been shown that depletion of the
cytoplasmic filaments has only a modest effect on the
overall efficiency and selectivity of nuclear import proc-
esses [15]. Eight filaments of approximately 75 nm in
length depart from the nuclear ring and join the distal ring
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forming the so-called "fishtrap" or nuclear basket [6].
Nuclear pore complexes are composed of approximately
30 different proteins (called nucleoporins), some of
which are integral and others are dynamically associated
with the main structural scaffold [16]. Several large nucle-
oporins have phenyalanine-glycine rich domains (FG-
rich). FG-rich domains are highly flexible and mobile, are
mostly unfolded and thus able to interact with many
binding partners simultaneously with fast association and
dissociation rates [6]. FG-rich nucleoporins are thought to
be essential to regulate kinetics and selectivity of nuclear
import by constituting a selective gating or permeability
barrier to molecules. Although the exact mechanisms are
not understood and there are several proposed models
[14,17-19], it is clear that nuclear import receptors, such
as importins, mediate passage of their cargos through this
mesh of FG-rich domains, possibly by conferring to the
cargos themselves an overall mildly hydrophobic prop-
erty and appropriate affinity for certain nucleoporins
[18,19]. This might be accomplished by the mildly hydro-
phobic nature typical of all importins examined so far
[19]. Importins would then act as "chaperones" for pro-
teins translocating across nuclear pore complexes.
Importins bind to their cargos through recognition of spe-
cific domains called nuclear localizing signals. The associ-
ation or dissociation of importins from cargoes depends
on the small GTPase Ran. In its GDP form, it promotes
association whereas in its GTP form it promotes dissocia-
tion [7-9]. A gradient of RanGTP is maintained across
nuclear pores by RanGAP1, RanBP1 and RanBP2 that
induce hydrolysis of RanGTP into RanGDP at the cyto-
plasmic face of nuclear pores. Conversely, RCC1 converts
RanGDP to RanGTP in the nucleus. NTF2 transports
RanGDP into the nucleus for conversion by RCC1 and
thus reconstitution of the nuclear RanGTP pool. So the
transport cycle begins in the cytoplasm by binding of the
appropriate importin to the cargo in the presence of
RanGDP (Figure 2). The cargo can now be chaperoned
across the nuclear pore complex. Once the cargo has
reached the nuclear side, in the presence of RanGTP, the
affinity of the importin for the cargo decreases dramati-
cally and the cargo is released and trafficked to the appro-
priate nuclear compartment [7-9] (Figure 2). There are
exceptions to this rule since some cargoes, like certain
hnRNPs, are shuttled across nuclear pores in a Ran-inde-
pendent way [20-22]. Although energy per se does not
seem to be required for translocation across nuclear pores
of simple cargoes in vitro, except for the generation of
RanGTP, hydrolysable GTP and ATP may be required for
nuclear import of large protein or nucleoprotein com-
plexes in vitro and in vivo [23-25].
Interestingly, nuclear pore complexes are dynamic and
respond to cellular stimuli. For example Ca2+ induces con-
formational changes to nuclear pore complexes and the
distal nuclear ring dilates in the presence of Ca2+ or con-
tracts in its absence. Thus the distal ring may function like
an iris-like gate and regulate passage of cargoes [12]. The
differentiation and proliferative state of the cell is also
likely to play a role. Nuclear uptake rate for large particles
is significantly higher in dividing cells compared to
growth-arrested or serum-starved cells and terminal differ-
entiation has been shown by electron micropscopy to
increase both the efficiency of nuclear import and the size
of imported particles through nuclear pores [26-28]. The
fact that larger particles are imported into the nucleus of
dividing cells with greater efficiency suggests that the per-
meability of nuclear pores may be subject to regulation,
perhaps by partly changing the composition of the pores
themselves. Moreover, nuclear import may also be modu-
lated by phosphorylation and cell metabolism [29,30]. I
propose that different regulation of the rate and overall
permeability of nuclear import in dividing versus non-
dividing cells and in differentiated versus undifferentiated
cells is likely to be relevant to nuclear import of retrovi-
ruses, as it will be discusses in more detail later.
The challenges facing viruses and the nuclear 
import system
Many viruses have to pass through nuclear pores to reach
the nucleus, thus three general problems become immedi-
ately obvious. First problem, the capsid of many viruses,
including adenoviruses, herpesviruses and retroviruses
exceed the maximum diameter for passage through
nuclear pores. Different viruses have evolved different sys-
tems to overcome this limit [31-34]. Some viruses, like
adenoviruses, dock their partially disassembled capsids to
the cytoplasmic face of nuclear pores, then the capsid
completes disassembly by a process called uncoating,
which leads to exposure of the viral nucleic acids to the
nuclear import machinery. Other viruses, like herpex sim-
plex virus, dock their capsids at the NE and eject the
nucleic acids directly into or very close to nuclear pores.
Yet other viruses uncoat in the cytoplasm and their
genome engages with the nuclear import machinery at an
earlier stage. It is likely that the overall structural stability
of the intracellular viral capsid, the need to maintain a
large genome tightly packed to facilitate cytoplasmic traf-
ficking and the need to carry out enzymatic reactions (as
in retroviruses) are all important factors in driving the
evolution of different strategies to uncoat and overcome
the size limit set by nuclear pores.
Second problem, regardless of how and where the uncoat-
ing step takes place, viral nucleic acids must be imported
into the nucleus against a steep gradient, since nucleic
acids are compacted to a very high density within the
nucleus itself (nearly 0.1 g/cm3 in lymphocytes) [35].
Some bacteriophages might have solved a similar prob-Retrovirology 2006, 3:74 http://www.retrovirology.com/content/3/1/74
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lem of introducing their genome into the bacterial host
cell by actively packing DNA into their capsid to a very
high density with a pressure reaching 6 MPa. Such internal
pressure is likely to provide sufficient force to inject the
phage DNA genome into the bacterial cell at the time of
infection [36]. However, there is no evidence so far that
mammalian viruses use a similar mechanism to inject
their genome into the nucleus.
Third problem, large nucleic acids molecules are charged
and hydrophilic. As mentioned earlier, passage through
the central channel of the nuclear pore complex depends
on hydrophobic interactions with the highly mobile phe-
nylalanine-glycine (FG)-rich domain of nucleoporins [6].
Thus, such large viral nucleoprotein complexes need to be
somehow appropriately chaperoned to transit across
nuclear pores.
Three-dimensional structure of the nuclear pore complex Figure 1
Three-dimensional structure of the nuclear pore complex. The main components of the pore include the central framework 
(yellow), the cytoplasmic ring moiety and attached filaments (blue), the nuclear ring moiety and the distal ring of the nuclear 
basket (orange). Nuclear membranes are depicted in grey. Reproduced with permission from Fahrenkrog B and Aebi U, 
Nature Reviews Molecular Cell Biology 4: 757–766 (2003) Macmillan Magazines Ltd.Retrovirology 2006, 3:74 http://www.retrovirology.com/content/3/1/74
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Schematic representation of the nuclear import cycle Figure 2
Schematic representation of the nuclear import cycle. The cargo (red) with a NLS binds impα and then impβ binds to impα 
forming a trimeric complex in the presence of RanGDP. The trimeric complex goes across nuclear pores and reaches the inner 
nuclear region. Here high levels of RanGTP induce a conformational change in impβ, which dissociates from the cargo and 
shuttles back to the cytoplasm. Impα binds to CAS in the nucleus and forms a complex with RanGTP. Such complex is 
exported from the nucleus and dissociates in the cytoplasm upon conversion of RanGTP into RanGDP. RanGDP is imported 
into the nucleus by NTF2. In the nucleus, RanGDP is rapidly converted into RanGTP by RCC1. At the cytoplasmic face of the 
nuclear pore, RanGTP in converted to RanGDP by RanGAP, RanBP1 and RanBP2. Thus a gradient of RanGTP across the 
nuclear envelope is maintained, which gives directionality to the import/export process.Retrovirology 2006, 3:74 http://www.retrovirology.com/content/3/1/74
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The interphase nucleus: not every retrovirus's 
club
Having broadly defined the general context and problems
relative to nuclear import of viruses' genome in mamma-
lian cells, let us now focus on retroviruses.
The ability of lentiviruses to infect terminally differenti-
ated, non-dividing cells has been taken as proof that the
genome of such viruses is imported into the nucleus. The
inability of simple retroviruses to infect non-dividing cells
on the other hand has been taken as proof that the
genome of such viruses cannot be imported into the
nucleus. The picture is not that clear-cut because different
retroviruses infect non-cycling cells with different effi-
ciency.
There is overwhelming evidence that lentiviruses infect
non-dividing cells with high efficiency. Caprine arthritis-
encephalitis virus (CAEV) has increased tropism for differ-
entiated macrophages both in vitro and in vivo [37-39]
and can infect dendritic cells [40]. Equine infectious anae-
mia virus (EIAV) is also found mainly in terminally differ-
entiated macrophages of infected horses [41]. SIV and
HIV infect differentiated macrophages, microglial cells
and intestinal mucosa resting memory CD4+ T cells [42-
51]. Clearly, the ability of lentiviruses to infect these types
of non-dividing cells is crucial for virus spread and disease
pathogenesis. Moreover, HIV-1 was found to be able to
infect cells arrested in the cell cycle by treatment with
aphidicolin or γ-irradiation and HIV-1 derived vectors
infect hematopoietic stem cells and neurons [52-54]. In
fact it appears that passage through mitosis is not a signif-
icant alternative pathway for HIV-1 infection even in
dividing cells although nuclear envelope breakdown can
modestly influence the kinetics of virus association with
chromatin [55-57].
On the other hand there is strong evidence that gamma-
retroviruses can efficiently infect only cycling cells, with
one notable exception [58-61]. The block to Moloney
murine leukaemia (MoMLV) infection in non-dividing
cells is up to 10,000 fold and it is independent of the spe-
cific phase of the cell cycle (i.e. G1/S or G2 or G0). The
virus can synthesize linear full length DNA but cannot
integrate or produce circular 2LTR DNA forms. Alpharet-
roviruses infect non-cycling cells more efficiently than
MLV but less efficiently than HIV [62-67]. Foamy viruses
also appear to have some ability to infect non-dividing or
slowly dividing cells [68,69], for example they can infect
human umbilical cord CD34+ cells and peripheral blood
lymphocytes quite efficiently [70-72]. It is possible how-
ever that foamy viruses' ability to infect non-dividing cells
depends on the long persistence of the pre-integration
complex inside infected cells, until division eventually
takes place [73].
So, why can lentiviruses infect non-dividing cells and
gammaretroviruses cannot? The basis for this difference
may reside in the uncoating process [2,74,75]. HIV-1
appears to shed its capsid shell quite early during infec-
tion, presumably in a manner that is timed with ongoing
reverse transcription [76,77]. Evidence to support early
HIV uncoating include the very low abundance of p24 CA
protein found associated with the reverse transcription
complex (RTC) and the PIC, the high density of the RTC/
PIC in linear sucrose gradients, structural and morpholog-
ical analyses of the RTC by electron microscopy, and the
ability of RNA aptamers, siRNA and certain nucleoprotein
complexes to interact with the incoming viral RNA
genome [76,78-86] (although siRNA targeting of incom-
ing viral RNA is not universally observed [87]). Clearly the
viral capsid must remain viable for some time after infec-
tion since it is targeted by TRIM5α and related TRIM5s,
which block reverse transcription, perhaps by anticipating
the uncoating process itself [88,89]. Recent kinetic analy-
ses suggest that the HIV-1 capsid remains viable for
approximately 30–60 minutes following entry and after
that it can no longer be targeted by TRIM5-CypA [90].
MLV, on the other hand, appears to maintain a capsid
shell at least until nuclear entry, as shown by electron
microscopy analyses of MLV-infected cells and biochemi-
cal studies of the RTC [91-93]. Indeed, substantial
amounts of p30 CA are associated with MLV RTCs
[92,93]. MLV RTCs synthesize full length viral DNA in the
endogenous reverse transcription assay in the presence of
small amounts of detergent, which presumably help per-
meabilize the capsid, and the interior of the MLV RTC can
be accessed by small molecules but not by antibodies
[92].
The viral capsid of both HIV-1 (broad end) and MLV has
a diameter of 60 nm or greater and cannot go across
nuclear pore complexes even by an active process. Thus
early uncoating may be a necessary, albeit probably not
sufficient, step for nuclear import. Two experimental lines
of evidence seem to support this possibility. Chimeric
viruses in which HIV-1 p24 CA protein has been swapped
with MLV p30 CA are unable to infect cells arrested in the
cell cycle, hence MLV CA appears to be a dominant-nega-
tive factor for nuclear import [74]. HIV-1 p24 CA mutant
that fails to dissociate from RTCs also block virus replica-
tion at the level of both nuclear import and integration
[75].
Although this is an appealing model to explain the pheno-
typic difference between HIV and MLV, there are some
aspects that merit attention. It is likely that MLV is also tar-
geted to the nucleus. For example, MLV mutants in the
p12gag protein synthesize normal levels of full length viral
DNA but fail to form 2LTR circles, perhaps because they
cannot associate properly with nuclear structures [94].Retrovirology 2006, 3:74 http://www.retrovirology.com/content/3/1/74
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Moreover, MLV p30 CA can be SUMOlated and mutants
in the p30 CA SUMO target region are blocked in the early
phases of replication [95]. This is an intriguing observa-
tion because SUMO is involved in nuclear targeting of
RanGAP1 to RanBP2, the constituent of the external fila-
ments of the NPC [96]. It is therefore tempting to propose
that MLV is actively targeted to components of the nuclear
pores, which are known to bind to mitotic spindles during
anaphase and early telophase [97]. This would then help
tethering MLV PICs to chromatin following cell division.
The Fv1 gene might directly or indirectly prevent such
interaction between nuclear pore components and MLV
PICs and hence prevent PIC nuclear retention, viral DNA
circularization and integration.
A recent observation that apparently does not quite fit
into the uncoating model for nuclear import suggests that
MLV can infect differentiated, post-mitotic macrophages
almost as efficiently as HIV-1 based vectors [61]. MLV
infection of macrophages is limited to a short time win-
dow and it is unlikely to occur in vivo. Nevertheless one
can still reconcile this finding with the uncoating model
by postulating that NPC permeability in a selected popu-
lation of macrophages may be greater than usual and
allow active passage of macromolecules with a diameter
of 60 nm. It will be interesting to test experimentally if this
is indeed the case. As mentioned earlier, NPC permeabil-
ity changes depending on the metabolic state of the cell,
its differentiation and its ability to divide. Alternatively,
MLV PICs may persist longer in macrophages until some
degree of uncoating takes place allowing nuclear import.
Nuclear import of HIV-1, facts and controversies
Uncoating of the viral capsid is likely to be a pre-requisite
for nuclear import but specific signals and import factors
are also likely to direct intracellular trafficking of the RTC/
PIC. Several such nuclear localisation signals (NLS) have
been identified in the HIV-1 PIC but no unequivocal pic-
ture has emerged yet. The first NLS within the HIV-1 PIC
was reported in the N-terminal region of p17gag MA and
mutation of two lysines at position 26 and 27 was shown
to block HIV-1 replication in terminally differentiated pri-
mary macrophages but not in proliferating cells [98].
These observations were quickly confirmed although it
appeared that Vpr also influenced HIV-1 infection of non-
dividing cells in addition to MA [80,99]. Moreover, phos-
phorylation of MA on a C-terminal tyrosine (Y131) was
reported to induce MA incorporation into PICs (via bind-
ing to integrase) and to be essential for HIV-1 infection of
non-dividing cells [100,101]. A more complex picture of
MA phosphorylation was proposed later since mutation
of MA Y131 did not appear to have an effect on virus repli-
cation [102,103].
Subsequently, however, three studies could not confirm
the presence of an NLS in MA [103-107]. The phenotype
of HIV-1 mutants in the N-terminal MA NLS also
remained controversial. Whilst such mutants were origi-
nally reported to be severely and selectively impaired in
primary macrophages, later reports showed that they were
moderately (2 to 15 fold) defective in both dividing and
non-dividing cells using spreading assays and single-cycle
assays [104,105]. Remarkably, HIV-1 mutants with large
deletions of the MA N-terminal region or even lacking the
entire MA (but retaining a short N-terminal myristoyla-
tion signal) have been shown to still be able to replicate
in both dividing cells and macrophages, albeit at reduced
levels [108].
More recently, MA has been reported to have a CRM1-
dependent nuclear export signal (NES). Mutations in this
NES at position 18 and 22 of MA were shown to cause
nuclear localisation/retention of viral RNA and severely
impair HIV-1 infectivity. Furthermore, the NES has been
proposed to override a presumably masked NLS in the
context of the p55gag polyprotein [109]. It is somewhat
difficult to reconcile these latter findings with earlier work
showing that deletions of MA from residues 8 to 87 have
a modest effect on HIV-1 replication [108], yet differences
in the HIV-1 strains used might at least in part account for
the different results. It is also interesting that the NLS and
NES in MA would appear to be separated by 4 residues
only [98,109], although a novel NLS in MA has been
reported [110]. In summary, although there is no agree-
ment on the existence of a NLS in HIV-1 MA [98,105-
107,109,111], there appears to be some consensus that
mutations in the N-terminal region of MA have a moder-
ate effect on virus infectivity in macrophages as well as
other dividing cell types. Since such an effect is also
detected in single-cycle assays, it is likely to involve some
early, post-entry event.
The viral protein R (Vpr) has been shown to play a role in
HIV-1 nuclear import (for a recent review on this subject
please refer to [112]). The general consensus is that Vpr is
a karyophilic protein. Indeed Vpr localises to the nucleus
when expressed on its own and also possesses at least two
transferable NLSs that induce nuclear accumulation if
fused to larger proteins like the maltose binding protein
or  β-galactosidase [113-118]. Vpr also localises to the
nuclear envelope, possibly by direct engagement with
nucleoporins [116-119]. The pathways used by Vpr for
nuclear import are not completely clear. Vpr is a small
protein of 96 aminoacids and contains no canonical
(SV40 T antigen/importin β binding domain [IBB] NLS).
The N-terminal region of Vpr contains a NLS, which can
bind to importin α and nucleoporins [116,118] yet Vpr is
not imported into the nucleus by the importin α/importin
β heterodimer [116-118,120]. An additional trasferrableRetrovirology 2006, 3:74 http://www.retrovirology.com/content/3/1/74
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NLS has been detected in the C-terminal region (aa 73–
96), which uses a pathway distinct from the N-terminal
NLS. Both C- and N-terminal NLSs were shown to use a
Ran-independent pathway and to require minimal energy
[117]. It has been proposed that Vpr bypasses the normal
requirements for nuclear import like Ran-dependent
interaction with nuclear import receptors and instead can
bind directly to nucleoporins, similar to importin β family
members [117,118].
Importantly, Vpr is incorporated into virions at high levels
via its interaction with the p6 domain of p55gag [121]. The
ability of Vpr to be incorporated into virions and enhance
infectivity in macrophages might in addition depend on
its nucleocytoplasmic shuttling properties and to a NES
located in the C-terminal region, although this possibility
is contentious and Vpr nuclear export may be more
important in regulating cell-cycle arrest [122,123]. Vpr is
retained in the RTC/PIC [76,80,83,124]. Thus, it has been
proposed that Vpr stimulates docking of the RTC to the
nuclear pores or alternatively disrupts nuclear envelope
and pores to alter nuclear permeability [125,126]. Indeed
many studies have shown that mutations in Vpr reduce
HIV-1 ability to replicate in different cell types, including
macrophages and PBMCs [80,116,118,127]. The replica-
tion defect is greater in cells infected a low MOI but is only
a few fold. Consistent with this phenotype, HIV-1 based
vectors that do not encode Vpr are still able to infect mac-
rophages and other non-dividing cell types [128]. Moreo-
ver, Rhesus monkeys infected with SIVmac strains with a
mutation in Vpx, which is the gene for nuclear import cor-
responding functionally to HIV-1 Vpr [129], showed
lower virus burden, delayed decline in CD4+ counts but
eventually progressed to AIDS [130]. Similarly, SIVsm
strains mutant in Vpx also showed delayed replication
kinetics in pigtailed macaques, possibly due to reduced
virus amplification at early, post-transmission stages
[131]. Taken together, these data suggest that the nuclear
import properties of HIV-1 Vpr are probably not essential
for virus replication but may increase HIV-1 infectivity
and ability to propagate in specific cell types.
Integrase remains stably associated with the RTC and later
the PIC and is the necessary protein for integration of viral
DNA into host chromosomes. Because of its tight associa-
tion with the PIC even after nuclear entry, integrase would
be a good candidate to mediate HIV-1 nuclear import.
HIV-1 integrase (IN) is karyophilic but there is some disa-
greement on the mechanisms regulating IN trafficking
into the nucleus. Most investigators have reported that IN
is imported into the nucleus by an active, saturable and
energy -dependent mechanism. Putative NLS have been
mapped to several regions of the C-terminus of IN
[111,132-134] and to the central catalytic domain
[135,136], although some of these putative NLSs have
been questioned [133,137,138]. Moreover, IN can bind to
importin α [25,111,138], to importin β directly [25,138]
as well as to importin 7 and transportin [25]. At least
importin α, importin β and importin 7 have been shown
to stimulate nuclear accumulation of IN in a Ran-depend-
ent way [25] and in one recent study blocking antibodies
against importin α and/or importin β were shown to
reduce IN nuclear import [138]. Antibodies against
importin 7 did not block IN nuclear import in one study
[138], however it is not clear which anti-imp7 antibodies
have been used in that study and to our knowledge anti-
bodies with good affinity for native importin 7 are not
available. Therefore those negative results should be inter-
preted with caution. Interestingly, it has been recently
reported that HIV-1 Rev binds to and is imported by a
number of importins, including importin β, importin 7
and transportin [139]. The adenoviral pVII protein, which
is tightly bound to the viral DNA and is thought to medi-
ate nuclear import of the adenoviral genome, has also
been shown to bind to and be imported by the impα/β
heterodimer, impβ alone, imp7 alone, imp7/β het-
erodimer and transportin [140]. Thus adenoviral pVII
protein and HIV-1 IN appear to behave in a remarkably
similar way [25,140]. Adenoviral pVII and HIV-1 Rev and
IN are all small, basic nucleic acids-binding proteins and
may share similar nuclear import pathways. Moreover,
relying on multiple importins may give a selective advan-
tage to viruses by maximising nuclear import efficiency in
different conditions and cell types. It is plausible that
some ribosomal proteins have adopted a similar strategy
to ensure their efficient nuclear import [141].
Lentiviral INs specifically bind to lens epithelium-derived
growth factor (LEDGF/p75), a hepatoma-derived growth
factor that interacts with DNA and this association has
been reported to be important for IN nuclear localisation
[142,143]. IN and LEDGF/p75 have been shown to co-
localise in nuclei following transfection of plasmids
encoding for the two proteins. Mutant IN unable to inter-
act with LEDGF/p75 was shown to have lost its ability to
accumulate into nuclei and siRNA-mediated knock down
of LEDGF/p75 induces re-localisation of exogenously
expressed IN to the cytoplasm [143-146]. These data point
to the possibility that LEDGF/p75 mediates nuclear
import of IN. However, pre-incubation of LEDGF/p75
with IN did not stimulate IN nuclear import in the nuclear
import assay [145]. Severe knock down of LEDGF/p75
inhibits HIV-1 infectivity at the level of integration but not
appreciably at the level of RTC nuclear import and the
nuclear rather than the cytoplasmic pool of LEGDF/p75
appears to be the important for HIV-1 replication ([147];
E. Poeschla personal communication). Since IN is readily
ubiquitinated in stably expressing cells lacking LEDGF/
p75 [144], such modification might cause loss of IN
nuclear import.Retrovirology 2006, 3:74 http://www.retrovirology.com/content/3/1/74
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Is it possible to reconcile these findings with the observa-
tion that, at least in vitro, IN can be imported into the
nucleus by an active mechanism in the absence of LEDGF/
p75? It is perhaps interesting that the integrase-binding
domain in LEDGF/p75 is structurally closely related to the
HEAT repeat found, amongst other proteins, in importin
β and other importins [148]. It is therefore tempting to
speculate that the very same region in IN mediating
LEDGF/p75 binding also mediates interaction with
importins via the HEAT motif. If this is the case, then alter-
native binding of LEDGF/p75 and importins might take
place. Importins binding to IN might prevail in the cyto-
plasm due to their relative abundance in this compart-
ment whilst LEDGF/p75 binding to IN might prevail in
the nucleus, following dissociation of importins from IN
in the presence of RanGTP. Then LEDGF/p75 might tether
IN to chromosomes and stimulate HIV-1 DNA integra-
tion. A prediction of this model is that LEDGF/p75 com-
petes with importins for binding to IN in the absence of
RanGTP though one would expect LEDGF/p75 to bind to
IN with greater affinity than importins.
Alternatively, lentiviral INs per se might not have a trans-
ferable NLS as shown by two reports [149,150] and
nuclear accumulation could simply be the result of diffu-
sion across nuclear pores, DNA binding and nuclear reten-
tion. LEDGF/p75 tethers IN to chromosomes, hence it
might appear to induce nuclear import.
Finally, a few words of caution should be spent on the role
of IN in HIV-1 nuclear import. There is limited informa-
tion on the precise conformation of IN within the RTC/
PIC and several domains, which are exposed in the recom-
binant protein, might not be available once the protein is
part of the RTC/PIC and bound to nucleic acids [132,151].
Moreover, it is now clear that IN serves multiple roles in
addition to viral DNA integration and that mutating puta-
tive IN NLSs may result in unexpected phenotypes unre-
lated to nuclear import [132,152-156]. Thus, it has
proven a rather difficult task to translate results obtained
in vitro by mutagenesis of IN into a clear phenotype of
reduced HIV-1 nuclear import. Remarkably, a recent study
has analysed the phenotype of HIV-1 chimeric viruses
bearing MLV IN in place of HIV-1 IN and shown that such
mutants are attenuated but still able to infect non-divid-
ing cells. Only a small increase was observed in the ratio
of cytoplasmic to nuclear viral DNA in cells infected with
the mutant virus compared with wild-type HIV-1 [157].
Thus, it is possible that IN does not play an important role
in HIV-1 nuclear import, although it should be noted that
MLV IN has also been shown to rapidly accumulate into
the nuclei of infected cells [91].
The central polypurine tract (cPPT) was also shown to
influence HIV-1 nuclear import. The cPPT is a second ori-
gin of DNA plus strand synthesis located in pol, it is
present in all lentiviruses and results in a short (approxi-
mately 100 nt) stretch of triple stranded DNA upon com-
pletion of reverse transcription [158,159]. Absence or
mutation of the cPPT was shown to abolish HIV-1 replica-
tion in a spreading assay and to reduce infectivity by 5–7
fold in single cycle infection assays using HIV-based vec-
tors. Reduced 2LTRs circular viral DNA formation and
hence nuclear import was reported to be the main defect
of the mutant viruses [160,161]. This observation has
been confirmed by many studies using HIV-1 based vec-
tors in several cell lines and primary human cells, includ-
ing PBMCs, T-lymphocytes, macrophages, CD34+ cells
and in rat neurons [162-165]. Indeed it is now standard
practice to include the cPPT element in the design of "sec-
ond and third generation" lentiviral vectors. A few fea-
tures of the phenotype of cPPT+ vectors are worth noting.
First, the cPPT+ vectors have increased infectivity in both
dividing and non-dividing cells. Second, cPPT+ vectors
appear to have an increased rate rather than an absolute
increase of HIV-1 DNA nuclear transport. Third, there
seem to be a slight increase in integration efficiency with
cPPT+ vectors and fourth, cPPT+ vectors are able to over-
come a saturation effect seen with cPPT- vectors, hence
they work better at high MOI [162-165]. This would lend
support to the hypothesis that the cPPT can "boost" HIV-
1 vector infection bypassing (partially) the requirement
for some limiting cellular factor important for nuclear
import.
The picture becomes more complicated when wild type
viruses with a normal or mutated cPPT are tested in
spreading assays. In this case a modest attenuation of
cPPT- viruses is seen only in some cell types and even in
single cycle assays the difference between cPPT- and
cPPT+ viruses' infectivity has been reported to be approx-
imately two fold [153,154]. A similar degree of inhibition
has been observed with the yeast Ty1 retrotransposon
lacking the cPPT element [166]. The reasons for this dis-
crepancy are not completely clear. One simple explana-
tion would be that virus growth in spreading assays is
generally measured by p24gag ELISA or by enzymatic RT
assays and both assays have higher variability than GFP
detection by FACS in single cycle assays. Thus, if the vari-
ability of the detection assay is greater than the experi-
mental difference to be observed, the results cannot be
accurately measured. Alternatively, a difference in the rate
rather than absolute amount of HIV-1 DNA nuclear
import may not be detectable in spreading assays due to
the highly asynchronous infection process, as opposed to
a more synchronous infection with viral vectors. Elements
in the HIV-1 genome, not included in viral vectors, might
also partially compensate for the lack of the cPPT.
Recently, a more severe replication defect, consistent with
the one found with HIV-1 based vectors, has beenRetrovirology 2006, 3:74 http://www.retrovirology.com/content/3/1/74
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reported for different HIV-1 strains lacking the cPPT ele-
ment in single cycle assays and spreading assays [167].
Even if the cPPT may not be absolutely essential for HIV-
1 replication, at least in tissue culture, this viral element
remains a very interesting biological phenomenon and
also has important practical applications in gene therapy.
Cellular factors
Mutations of all known viral karyophilic elements does
not block HIV-1 replication [157], suggesting that viral
components are unlikely to be the only factors regulating
HIV-1 nuclear transport and that cellular factors need also
to be investigated. One major problem in this case was the
lack of a convenient in vitro assay to screen for potential
cellular factors with HIV-1 nuclear import ability. The
field of nuclear import has advanced at an impressive pace
since the introduction in the early '90s of the so-called
"nuclear import assay" [168] (Figure 3). In this assay, the
cell plasma membrane is permeabilized with digitonin,
which solubilises cholesterol and hence leaves the nuclear
envelope intact. Soluble intracellular components are
washed out in buffer and nuclear import is artificially
reconstituted by the addition of the fluorescent-tagged
substrate of interest, cytoplasmic extracts or specific cellu-
lar factors, the Ran system and an energy regenerating sys-
tem. The cells are incubated at 25 to 37°C for a short time,
fixed and then analysed by confocal microscopy. Nuclear
accumulation of the tagged substrate is detected when the
right cellular components are added. Thus, this assay has
allowed screening for many factors and has led to the
identification of several importins or karyopherins [168-
171].
We have adapted this assay to investigate cellular compo-
nents involved in HIV-1 nuclear trafficking (Figure 3).
Purified HIV-1 RTCs are fluorescently labelled and added
to the permeabilised cells, which can be HeLa or primary
macrophages. This approach does not depend on muta-
tions of viral proteins and putative nuclear import com-
ponents can be tested individually, thus multiple and
potentially redundant import pathways can be identified
and dissected.
Using this approach we have recently found that importin
7 (imp7) stimulates nuclear import of HIV-1 RTCs and
that siRNA-mediated depletion of imp7 inhibits HIV-1
infection, though only by a few fold [25]. Another study,
however, using the siRNA approach, failed to see a pheno-
type in imp7 knock down cells and primary macrophages
[172]. It should be noted that conflicting results were also
reported for RNAi-mediated knock down of LEDGF/p75,
which have cast doubts on the biological relevance of this
proteins for HIV-1 replication [143,147,173]. A more rad-
ical knock-down of LEDGF/p75 has recently been
reported to significantly affect viral replication, highlight-
ing the fact that even small amounts of cellular factors are
often sufficient to support normal HIV-1 replication (E.
Poeschla, personal communication). The unambiguous
role of LEDGF/p75 in HIV-1 replication is supported by
recent LEDGF/p75 knock out studies (A. Engelman, per-
sonal communication). We have since observed that the
efficiency HIV-1 but not SIVmac infection is reduced in
stable imp7 shRNA knock down cell lines (Fassati et al.
unpublished). However, the development of effective
imp7 dominant negative mutants or cells with a condi-
Schematic representation of the nuclear import assay Figure 3
Schematic representation of the nuclear import assay. (A) 
The classic assay. Cells are permeabilized with digitonin, 
which leaves the nuclear envelope intact. The cytosol is 
washed out and nuclear import is reconstituted by addition 
of the protein of interest (labelled fluorescently), cytosolic 
extracts or nuclear import receptors, the Ran system 
(RanGDP, NTF2, RanGAP, RanBP1) and an energy regener-
ating system. Accumulation of the protein of interest is 
examined by confocal microscopy. (B) Adapted assay. The 
assay is carried out as described above but purified and 
labelled HIV-1 RTCs are used instead of the protein of inter-
est.Retrovirology 2006, 3:74 http://www.retrovirology.com/content/3/1/74
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tional imp7 knock out will probably be needed to investi-
gate the full impact of this protein on the replication of
HIV-1 and other retroviruses.
More recently we seek to identify additional cellular fac-
tors involved in nuclear import of HIV-1 RTCs. Using
chromatographic procedures and the nuclear import assay
we have isolated a near-homogeneous fraction from cyto-
plasmic extracts. This fraction contained tRNAs, most of
them with defective 3' CCA ends. When synthesized in
vitro, such tRNAs promoted HIV-1 RTC nuclear import.
Moreover, tRNAs with RTC nuclear import activity were
incorporated into and recovered from virus particles. We
found that the anticodon loop mediated binding to the
viral complex whilst the T-arm may interact with cellular
components involved in nuclear import. These tRNAs spe-
cies were transported into the nucleus on their own in a
energy- and temperature-dependent way. We also
observed that HIV-1 mutant containing MLV gag [74] did
not incorporate tRNA species capable of promoting HIV-
1 RTC nuclear import and were impaired in infecting cell
cycle-arrested cells [174]. Thus, by investigating HIV-1
nuclear import, we have found evidence for retrograde
tRNA transport in mammalian cells, an unexpected proc-
ess that has also been recently described in yeast
[175,176]. Future work will hopefully elucidate which cel-
lular factors participate in these events and whether the
biological function of tRNA retrograde transport in mam-
malian cells is to modulate protein synthesis or is a tRNA
quality control mechanism or both.
Conclusion
Elucidating the mechanisms of HIV-1 nuclear import is
clearly a challenging area of research, both from a techni-
cal and a conceptual point of view. It is also a promising
area of research, likely to reveal new and fundamental cel-
lular pathways. To gain more insight and perhaps a little
inspiration, it may be wise to look at similar processes
occurring in cells, like mRNA export. Export of mRNA
nucleoproteins (mRNPs) involves several factors. One of
the best characterized is TAP or nuclear export factor 1
(NXF1) [177]. At least six other members of the NXF fam-
ily have been described, some having little export activity,
others having an mRNA-specific or cell type-specific
export activity [177]. Interestingly, despite their sequence
and structural similarity, different NXFs can use different
export pathways and different modes to bind to NPCs
[178]. NXFs need adaptors to engage with NPCs. One
such adaptor is p15, which allows TAP bindng to nucleop-
orins. NXFs need adaptors also to bind to mRNAs. The so-
called REF protein is an adaptor for TAP but additional
adaptors include several exon-exon junction complex pro-
teins. Moreover, the structure, shape and maturation stage
of mRNAs influence their export rate and ATP-dependent
motor proteins are required, probably at more than one
stage [177]. The level of complexity and sometimes
redundancy typical of mRNA export is well suited to illus-
trate the point: HIV-1 nuclear import is very likely to
involve a similar or higher degree of complexity.
In conclusion, I would now like to propose a model on
HIV-1 nuclear import. Many parts of this model are still
hypothetical; nonetheless I shall be bold enough to put it
to the attention and critical mind of the reader. After
entry, HIV-1 starts reverse transcription and shortly there-
after sheds, partially or completely, its capsid. Such shed-
ding is sufficient to expose the nucleoprotein complex or
RTC, composed of the viral genome (presumably still in
part RNA) and some viral and cellular proteins. The RTC
then engages with the nuclear import machinery at several
levels. There might be adaptors, both viral (for example
Vpr) and cellular (for example tRNAs), that promote RTC
docking and binding to the nuclear pores. Once at the
nuclear pore, additional signals/factors may facilitate the
charged and hydrophilic nucleic acids to cross the pore's
central channel (for example imp7), and other elements
may recruit putative motors at the pore to overcome the
steep DNA concentration gradient in the nucleus (for
example the cPPT element?). RTCs are likely to undergo
substantial conformational changes at different stages
(RTCs convert from RNA into double stranded DNA) and
viral and cellular factors are also likely to associate and
dissociate dynamically from the RTC. The multiplicity of
signals ensures that the rate of nuclear transport is fast and
individual signals may predominate in specific cell types.
Like a good orchestra, the loss of one element will reduce
the quality of the performance but, depending on the ele-
ment lost, it may be noticeable only to the educated ear. It
will be important to identify possible bottlenecks in this
process to develop effective anti-viral strategies. MLV, on
the other hand, may not be able to shed enough capsid to
make its RTC fully visible to the nuclear import machinery
and/or may lack sufficiently strong NLS [179]. MLV may
be docked close to or at nuclear pores but then it may have
to wait patiently until it is tethered to chromatin only after
dissolution of the nuclear envelope.
There is of course a fundamental question worth consid-
ering: why mammalian cells have an evolutionary con-
served mechanism to import DNA into their nuclei?
Perhaps the study of nuclear import of viral genomes will
shed some light on this problem too.
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